Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

LYRA vs KROS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KROS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–1 Matrix Metrics)

KROS Overall Winner 6-Pillar Tally: LYRA 0 – 5 KROS (1 Tie) Matrix Metrics: LYRA 1 – 8 KROS

As of Nov 17, 2026, Keros Therapeutics, Inc. (KROS) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas KROS carries 52.2/100 (HOLD) at $11.16 (48.8x Forward P/E, -172.4% operating margin).

  • Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile KROS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LYRA vs KROS
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82
KROS NASDAQ Head-to-Head Winner
Keros Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$11.16
+11.27% 1D
Market Cap $202.1M
TTM Revenue $41M
Forward P/E 48.8x
Beta / 30D Vol 1.11β · 67% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 55.0 Fund 64.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 56
RSI-14: 56.1 · SMA20: $10.57 · SMA50: $11.01

6-Pillar Scorecard Institutional Category Breakdown (LYRA 0 – 5 KROS)

Columns: Metric · LYRA · KROS
1. Valuation Multiples KROS
Forward P/E N/M 48.8x
Trailing P/E N/M 48.8x
PEG Ratio N/M N/M
EV / Revenue 3.9x N/M
2. Growth & Scale KROS
Revenue Growth (YoY) -87.2% +180.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $600,000 $41M
Market Cap $2.3M $202.1M
3. Profitability & Quality KROS
Gross Margin N/A -82.4%
Operating Margin -25032.0% -172.4%
Net Profit Margin 0.0% -151.4%
Return on Equity (ROE) -404.5% -12.6%
4. Balance Sheet & Cash Flow KROS
Cash Generation (TTM) -$32M EBITDA -$48M
Cash Flow Margin N/A -118.4%
Net Cash / Leverage -404.5% ROE $244M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KROS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 60.8% (10th %ile)
Put/Call OI Skew N/A 7.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LYRA (1) vs KROS (8)
Institutional Metric LYRA KROS Criterion Row Edge
Market Capitalization
Scale
$2.3M $202.1M Larger Scale KROS
Trailing P/E Ratio
Valuation
N/M 48.8x Lower Multiple KROS
Forward P/E Ratio
Valuation
N/M 48.8x Lower Multiple KROS
Revenue Growth (YoY)
Growth
-87.2% +180.5% Higher Growth KROS
Operating Margin (TTM)
Profitability
-25032.0% -172.4% Higher Margin KROS
Net Profit Margin
Profitability
0.0% -151.4% Higher Margin LYRA
Return on Equity (ROE)
Capital Efficiency
-404.5% -12.6% Higher ROE KROS
52-Week Range Position
Momentum
1% ($0–$38) 16% ($9–$23) Stronger Trend KROS
Beta / 30D Volatility
Risk Regime
0.33β · 248% Vol 1.11β · 67% Vol Lower Realized Risk KROS
Unified Institutional Score
Composite Signal
52.2 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$600,000 $41M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -82.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M EBITDA (-404.5% ROE) -$48M ($244M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KROS +28.91 pp
LYRA: -62.5% · KROS: -33.59%
3M Horizon KROS +38.47 pp
LYRA: -87.62% · KROS: -49.15%
6M Horizon KROS +51.04 pp
LYRA: -87.14% · KROS: -36.1%
1Y Horizon KROS +51.04 pp
LYRA: -87.14% · KROS: -36.1%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LYRA Revenue KROS Revenue LYRA Op. Margin KROS Op. Margin Margin Leader
FY2019 N/A $10M N/A -105.6% KROS
FY2021 $0M $20M -15303.5% -280.5% KROS
FY2022 $0M N/A -4131.0% N/A LYRA
FY2023 $0M $0M -4308.1% -112543.7% LYRA
FY2024 $0M $0M -6280.8% -5939.0% KROS
FY2025 $0M $240M -7794.5% 27.7% KROS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KROS CONSOLIDATION
92d in phase · OBV ACCUMULATION
Current IV 60.8%
IV Percentile 10th %ile
Put/Call OI Skew 7.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact KROS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KROS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $202.1M market capitalization and -172.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LYRA vs KROS Key Questions & Quantitative Answers

As of Nov 17, 2026, Keros Therapeutics, Inc. (KROS) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas KROS carries 52.2/100 (HOLD) at $11.16 (48.8x Forward P/E, -172.4% operating margin). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile KROS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KROS leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with KROS at +180.5% YoY revenue growth and +0.0% YoY earnings growth on $41M TTM revenue (-82.4% gross margin, -172.4% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), LYRA cumulative revenue shifted N/A while KROS shifted +2300.0%. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KROS.

KROS screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas KROS trades at 48.8x Forward P/E, 48.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (-118.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus KROS (-12.6% ROE) capital efficiency.

In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, KROS carries 60.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 7.00x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.11β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.